Comparative Detection of Lymph Node Micrometastases of Stage II Colorectal Cancer by Reverse Transcriptase Polymerase Chain Reaction and Immunohistochemistry

Shingo Noura(Osaka Rosai Hospital), Morito Monden(Unknown), Mitsugu Sekimoto(Kansai Medical University), Masataka Ikeda(Hyogo Medical University), Norikazu Masuda(Kyoto University), Yasuhiro Miyake(High Energy Accelerator Research Organization), Hirofumi Yamamoto(Osaka Gakuin University), Hiroki Fukunaga(Osaka Gakuin University), Tadashi Ohnishi(Osaka City University), Nariaki Matsuura∥(Osaka International Cancer Institute), Takashi Matsumoto(Aso Iizuka Hospital), Masakazu Ikenaga(Osaka National Hospital), Osamu Takayama(Osaka Gakuin University)
Journal of Clinical Oncology
October 11, 2002
10.1200/jco.2002.10.023
Cited by 137

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|983